01—Abstract
Summary
Summary of the 10-K filed February 22, 2008. Cited figures are marked; the original filing is the authoritative source.
Bristol-Myers Squibb Company (BMY) filed its 2007 10-K on February 22, 2008, detailing a year of significant strategic shifts and product performance.
The company divested its Medical Imaging business and made strategic acquisitions, including Adnexus Therapeutics, indicating a focus on streamlining operations and investing in future growth areas, particularly in biologics. Financially, BMY saw a robust 12% increase in worldwide net sales to $19.3 billiona, driven by strong performance in key pharmaceutical products like PLAVIX® and ABILIFY®, despite declines in mature brands such as PRAVACHOL® due to generic competition.
The company also announced an 11%b increase in its common stock dividend, signaling confidence in its financial health and future prospects. However, the company also reported significant charges related to its Productivity Transformation Initiative and impairments on auction rate securities, underscoring the ongoing efforts to optimize costs and manage financial market risks.
02—Key points
Key Highlights
- Worldwide net sales increased by 12% to $19.3 billion, driven by strong growth in key pharmaceutical products like PLAVIX® and ABILIFY®, offsetting declines in mature brands like PRAVACHOL® due to generic competition.
- The company divested its Medical Imaging business in January 2008 and acquired Adnexus Therapeutics in October 2007, signaling a strategic shift towards streamlining operations and investing in biologic therapies.
- BMY announced an 11% increase in its quarterly common stock dividend, the first since 2002, indicating management's confidence in the company's financial stability and future earnings.
- Significant charges were recorded related to the company's three-year Productivity Transformation Initiative (PTI), aimed at cost reduction and operational streamlining, with an expected $1.5 billion in annual cost savings by 2010.
- The company reported an impairment charge of $275 million on its investment in auction rate securities (ARS) due to market deterioration, highlighting exposure to credit market risks.
- Research and development spending increased by 10% to $3.3 billion, reflecting continued investment in the company's pipeline and focus on unmet medical needs.
- The company faced ongoing patent litigation concerning PLAVIX®, with an appeal pending from Apotex, highlighting the material impact that generic competition and patent challenges can have on the company's financial performance.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2007, Bristol Myers Squibb Co kept $0.14.
- Revenue$15.62B100.0%
- Cost of revenue−$4.92B31.5%
- Gross profit$10.70B68.5%
- Operating costs−$9.40B60.2%
- Operating income$1.30B8.3%
- Interest, other & tax$869.0M5.6%
- Net income$2.17B13.9%
Where FY2007 revenue went
$15.62B- Cost of revenue: $4.92B, 31% of revenue
- SG&A: $3.94B, 25% of revenue
- R&D: $3.16B, 20% of revenue
- Other operating costs: $2.30B, 15% of revenue
- Operating income: $1.30B, 8.3% of revenue
Kept 8.3% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2007filed February 22, 2008Financial Statements
05—Questions
Frequently Asked Questions
What were the key drivers of Bristol-Myers Squibb's sales growth in 2007?
Bristol-Myers Squibb's sales growth in 2007 was primarily driven by strong performance in key pharmaceutical products, notably PLAVIX® (clopidogrel bisulfate) which saw a 46% increase in sales despite the lingering impact of generic competition. Other significant contributors included ABILIFY® (aripiprazole), the SUSTIVA® Franchise (efavirenz), REYATAZ® (atazanavir sulfate), AVAPRO®/AVALIDE® (irbesartan/irbesartan-hydrochlorothiazide), and ERBITUX® (cetuximab). Newer specialty and biologic medicines such as BARACLUDE® (entecavir), ORENCIA® (abatacept), and SPRYCEL® (dasatinib) also showed strong sales, alongside the launch of IXEMPRA® (ixabepilone).
How did the company's strategic initiatives, such as the Productivity Transformation Initiative (PTI), impact its financial results?
The company initiated a three-year Productivity Transformation Initiative (PTI) aimed at reducing costs, streamlining operations, and rationalizing its global manufacturing network. This initiative is on track to achieve $1.5 billion in annual cost savings and cost avoidance by 2010. However, the implementation of the PTI resulted in charges estimated between $0.9 billion to $1.1 billion pre-tax, with $292 million incurred in 2007 and approximately $500 million expected in 2008. These charges impacted the company's reported earnings but are part of a strategy to enhance nimbleness and flexibility.
What are the primary risks and challenges facing Bristol-Myers Squibb as highlighted in the filing?
The filing highlights several key risks and challenges. Competition from other pharmaceutical manufacturers, particularly from lower-priced generic products, is a major concern, with the potential loss of market exclusivity for products like PLAVIX® being material. The ongoing patent litigation with Apotex concerning PLAVIX® presents a significant risk, as a favorable outcome for Apotex on appeal could lead to renewed generic competition. Additionally, the company faces risks related to manufacturing and supply chain disruptions, difficulties in developing and commercializing new products, adverse outcomes in various legal proceedings, and negative impacts from U.S. and foreign regulations and pricing pressures from managed care organizations and government agencies.
How did the company's investments in R&D and strategic alliances contribute to its performance?
Bristol-Myers Squibb significantly invests in research and development, with spending increasing by 10% to $3.3 billion in 2007. This investment is focused on addressing areas of significant unmet medical need and expanding the value of existing products. The company also actively pursues strategic alliances and collaborations, such as those with Sanofi for PLAVIX® and AVAPRO®/AVALIDE®, Otsuka for ABILIFY®, ImClone for ERBITUX®, and Gilead for ATRIPLA®. These alliances are crucial for sharing development costs, accessing new technologies, and expanding market reach, complementing internal R&D efforts.
06—Continue